Perturbation-response genes reveal signaling footprints in cancer gene expression

[1]  Sven Rahmann,et al.  Genome analysis , 2022 .

[2]  M. Landthaler,et al.  An immediate–late gene expression module decodes ERK signal duration , 2017, Molecular systems biology.

[3]  V. Grinkevich,et al.  Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis. , 2017, Cancer cell.

[4]  A. Eggermont,et al.  Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades , 2016, Oncoimmunology.

[5]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[6]  Mariano J. Alvarez,et al.  Network-based inference of protein activity helps functionalize the genetic landscape of cancer , 2016, Nature Genetics.

[7]  Y. Bossé,et al.  Latrophilin receptors: novel bronchodilator targets in asthma , 2016, Thorax.

[8]  S. Murphy,et al.  The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer—A potential therapeutic target , 2016, Molecular carcinogenesis.

[9]  L. Bullinger,et al.  Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia , 2015, International journal of cancer.

[10]  Y. Haupt,et al.  Faculty Opinions recommendation of Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. , 2015 .

[11]  P. Heath,et al.  Binding loci of RelA-containing nuclear factor-kappaB dimers in promoter regions of PHM1-31 myometrial smooth muscle cells. , 2015, Molecular human reproduction.

[12]  M. Bhatia,et al.  Innate immune response of human pluripotent stem cell-derived airway epithelium , 2015, Innate immunity.

[13]  Gary D Bader,et al.  Pathway and network analysis of cancer genomes , 2015, Nature Methods.

[14]  J. Asara,et al.  Metabolic signature identifies novel targets for drug resistance in multiple myeloma. , 2015, Cancer Research.

[15]  N. Matsumura,et al.  IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer , 2015, British Journal of Cancer.

[16]  P. Oefner,et al.  Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism , 2015, Oncotarget.

[17]  M. Rivera,et al.  Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways , 2015, eLife.

[18]  G. M. Di Guglielmo,et al.  aPKC alters the TGF&bgr; response in NSCLC cells through both Smad-dependent and Smad-independent pathways , 2015, Journal of Cell Science.

[19]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[20]  Y. Chun,et al.  Keratinocyte-derived IL-24 plays a role in the positive feedback regulation of epidermal inflammation in response to environmental and endogenous toxic stressors. , 2014, Toxicology and applied pharmacology.

[21]  V. Soumelis,et al.  Human blood BDCA-1 dendritic cells differentiate into Langerhans-like cells with thymic stromal lymphopoietin and TGF-β. , 2014, Blood.

[22]  Michael L. Gatza,et al.  An integrated genomics approach identifies drivers of proliferation in luminal subtype human breast cancer , 2014, Nature Genetics.

[23]  M. Jarzab,et al.  Global Gene Expression Profiling in Three Tumor Cell Lines Subjected to Experimental Cycling and Chronic Hypoxia , 2014, PloS one.

[24]  Ho-June Lee,et al.  Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. , 2014, Cancer cell.

[25]  D. Hwang,et al.  Integration of proteomic and transcriptomic profiles identifies a novel PDGF-MYC network in human smooth muscle cells , 2014, Cell Communication and Signaling.

[26]  D. Rodenhiser,et al.  Genome-Wide Analysis in Human Colorectal Cancer Cells Reveals Ischemia-Mediated Expression of Motility Genes via DNA Hypomethylation , 2014, PloS one.

[27]  H. Shankaran,et al.  ERK Oscillation-Dependent Gene Expression Patterns and Deregulation by Stress Response , 2014, Chemical research in toxicology.

[28]  E. Campo,et al.  Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma , 2014, Oncotarget.

[29]  G. Brumatti,et al.  Interleukin‐3‐mediated regulation of β‐catenin in myeloid transformation and acute myeloid leukemia , 2014, Journal of leukocyte biology.

[30]  L. Heasley,et al.  Hypoxia Regulates Alternative Splicing of HIF and non-HIF Target Genes , 2014, Molecular Cancer Research.

[31]  A. Ashworth,et al.  Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress , 2014, Nucleic acids research.

[32]  Ashley M. Zehnder,et al.  Enhancer-targeted genome editing selectively blocks innate resistance to oncokinase inhibition , 2014, Genome research.

[33]  P. Bushel,et al.  p53 and NF-κB coregulate proinflammatory gene responses in human macrophages. , 2014, Cancer research.

[34]  Jianmin Wu,et al.  Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling , 2014, Cell.

[35]  Y. Yarden,et al.  Structure and function of epigen, the last EGFR ligand. , 2014, Seminars in cell & developmental biology.

[36]  Jason Li,et al.  Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. , 2014, Cancer discovery.

[37]  G. Reifenberger,et al.  Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells , 2014, Molecular Cancer Therapeutics.

[38]  S. Pileri,et al.  Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway , 2014, Leukemia.

[39]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[40]  R. Guthke,et al.  Novel application of multi-stimuli network inference to synovial fibroblasts of rheumatoid arthritis patients , 2014, BMC Medical Genomics.

[41]  H. Popper,et al.  Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model – role of tumor stroma cells , 2014, BMC Cancer.

[42]  A. Levine,et al.  Tumor-Associated Mutant p53 Drives the Warburg Effect , 2013, Nature Communications.

[43]  L. Álvarez-Vallina,et al.  Lipopolysaccharide Activates Toll-like Receptor 4 (TLR4)-mediated NF-κB Signaling Pathway and Proinflammatory Response in Human Pericytes* , 2013, The Journal of Biological Chemistry.

[44]  H. Fröhlich,et al.  TGF-beta1 Does Not Induce Senescence of Multipotent Mesenchymal Stromal Cells and Has Similar Effects in Early and Late Passages , 2013, PloS one.

[45]  Phillip Owens,et al.  Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. , 2013, Cancer research.

[46]  Brooke Bullock Lao,et al.  Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling , 2013, Proceedings of the National Academy of Sciences.

[47]  N. Aceto,et al.  Mammary tumor formation and metastasis evoked by a HER2 splice variant. , 2013, Cancer research.

[48]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[49]  T. Kodama,et al.  The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases. , 2013, Cell reports.

[50]  M. Netea,et al.  IFN-γ-Stimulated Neutrophils Suppress Lymphocyte Proliferation through Expression of PD-L1 , 2013, PloS one.

[51]  Jinsong Liu,et al.  TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. , 2013, Cancer research.

[52]  Shihab Hasan,et al.  Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania somnifera’s key metabolite Withaferin A , 2013, In Silico Pharmacology.

[53]  F. Venet,et al.  Identification of Biomarkers of Response to IFNg during Endotoxin Tolerance: Application to Septic Shock , 2013, PloS one.

[54]  Y. Zhong,et al.  Early growth response protein-1 mediates lipotoxicity-associated placental inflammation: role in maternal obesity. , 2013, American journal of physiology. Endocrinology and metabolism.

[55]  Johannes M. Freudenberg,et al.  Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells , 2013, Nucleic acids research.

[56]  Bertram Klinger,et al.  Supplementary Materials for : Network quantification of EGFR signaling unveils potential for targeted combination therapy , 2022 .

[57]  Vassilis G Gorgoulis,et al.  Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. , 2013, Cancer cell.

[58]  Jeffrey J Meyer,et al.  Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5) , 2013 .

[59]  F. Chibon,et al.  Cancer gene expression signatures - the rise and fall? , 2013, European journal of cancer.

[60]  S. Orlow,et al.  IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis , 2013, The Journal of investigative dermatology.

[61]  Delong Liu,et al.  MEK and the inhibitors: from bench to bedside , 2013, Journal of Hematology & Oncology.

[62]  Kajia Cao,et al.  Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. , 2013, Blood.

[63]  Michal Sheffer,et al.  Pathway-based personalized analysis of cancer , 2013, Proceedings of the National Academy of Sciences.

[64]  G. Melillo,et al.  Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells. , 2013, The Journal of clinical investigation.

[65]  F. Iorio,et al.  Transcriptional data: a new gateway to drug repositioning? , 2013, Drug discovery today.

[66]  Jean-Paul Issartel,et al.  Hypoxia-induced expression of VE-cadherin and filamin B in glioma cell cultures and pseudopalisade structures , 2013, Journal of Neuro-Oncology.

[67]  T. Graeber,et al.  Type I Interferon Suppresses Type II Interferon–Triggered Human Anti-Mycobacterial Responses , 2013, Science.

[68]  J. Tabernero,et al.  Development of PI3K inhibitors: lessons learned from early clinical trials , 2013, Nature Reviews Clinical Oncology.

[69]  Jan Koster,et al.  FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma. , 2013, Cancer research.

[70]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[71]  P. J. Munson,et al.  Upregulation of α-synuclein during localized radiation therapy signals the association of cancer-related fatigue with the activation of inflammatory and neuroprotective pathways , 2013, Brain, Behavior, and Immunity.

[72]  Shalom Madar,et al.  Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53. , 2013, Carcinogenesis.

[73]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[74]  J. Lee,et al.  PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. , 2013, Cancer research.

[75]  V. Tabor,et al.  Targeting PI3K/Akt represses Hypoxia inducible factor-1α activation and sensitizes Rhabdomyosarcoma and Ewing’s sarcoma cells for apoptosis , 2013, Cancer Cell International.

[76]  Quanyi Lu,et al.  DNMT3A mutations and clinical features in Chinese patients with acute myeloid leukemia , 2013, Cancer Cell International.

[77]  D. Lenze,et al.  Global gene expression changes of in vitro stimulated human transformed germinal centre B cells as surrogate for oncogenic pathway activation in individual aggressive B cell lymphomas , 2012, Cell Communication and Signaling.

[78]  H. Rehrauer,et al.  Targeting the Phosphoinositide 3-Kinase p110-α Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[79]  L. Rasmussen,et al.  No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells , 2012, Molecular and Cellular Endocrinology.

[80]  K. Hirasawa,et al.  Suppression of IFN-Induced Transcription Underlies IFN Defects Generated by Activated Ras/MEK in Human Cancer Cells , 2012, PloS one.

[81]  O. de Backer,et al.  TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells , 2012, BMC Cancer.

[82]  R. Geffers,et al.  IPH-926 lobular breast cancer cells harbor a p53 mutant with temperature-sensitive functional activity and allow for profiling of p53-responsive genes , 2012, Laboratory Investigation.

[83]  L. Terracciano,et al.  Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. , 2012, Gastroenterology.

[84]  M. McMahon,et al.  Analysis of mRNA Profiles after MEK1/2 Inhibition in Human Pancreatic Cancer Cell Lines Reveals Pathways Involved in Drug Sensitivity , 2012, Molecular Cancer Research.

[85]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[86]  J. Gregg,et al.  Modulation of blood cell gene expression by DHA supplementation in hypertriglyceridemic men. , 2012, The Journal of nutritional biochemistry.

[87]  N. López-Bigas,et al.  Inhibition of Specific NF-κB Activity Contributes to the Tumor Suppressor Function of 14-3-3σ in Breast Cancer , 2012, PloS one.

[88]  W. Sellers,et al.  Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations , 2012, Molecular Cancer Therapeutics.

[89]  Thomas Häupl,et al.  The multifaceted balance of TNF-α and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines , 2012, Journal of Molecular Medicine.

[90]  C. Larsson,et al.  Prolactin Receptor in Primary Hyperparathyroidism – Expression, Functionality and Clinical Correlations , 2012, PloS one.

[91]  U. Völker,et al.  Regulation of Interferon-Inducible Proteins by Doxorubicin via Interferon γ-Janus Tyrosine Kinase-Signal Transducer and Activator of Transcription Signaling in Tumor Cells , 2012, Molecular Pharmacology.

[92]  P. Sorger,et al.  Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.

[93]  C. O'brien,et al.  Hypoxia regulated gene transcription in human optic nerve lamina cribrosa cells in culture. , 2012, Investigative ophthalmology & visual science.

[94]  T. Sutter,et al.  EGFR regulation of epidermal barrier function. , 2012, Physiological genomics.

[95]  Qisheng Li,et al.  HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. , 2012, Gastroenterology.

[96]  James T. Elder,et al.  Heterogeneity of Inflammatory and Cytokine Networks in Chronic Plaque Psoriasis , 2012, PloS one.

[97]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[98]  R. Grenman,et al.  Keratinocyte Growth Factor Induces Gene Expression Signature Associated with Suppression of Malignant Phenotype of Cutaneous Squamous Carcinoma Cells , 2012, PloS one.

[99]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[100]  T. Gilmer,et al.  Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations , 2012, Molecular Cancer Therapeutics.

[101]  M. Broggini,et al.  RAS/RAF/MEK inhibitors in oncology. , 2012, Current medicinal chemistry.

[102]  O. Emanuelsson,et al.  Combined Chromatin and Expression Analysis Reveals Specific Regulatory Mechanisms within Cytokine Genes in the Macrophage Early Immune Response , 2012, PloS one.

[103]  Jianli Wu,et al.  Functional interaction between responses to lactic acidosis and hypoxia regulates genomic transcriptional outputs. , 2012, Cancer research.

[104]  Jung S. Byun,et al.  ELL facilitates RNA polymerase II pause site entry and release , 2012, Nature Communications.

[105]  M. Suárez-Fariñas,et al.  A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin , 2011, The Journal of investigative dermatology.

[106]  Avi Ma'ayan,et al.  Expression2Kinases: mRNA profiling linked to multiple upstream regulatory layers , 2012, Bioinform..

[107]  C. Chung,et al.  Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma , 2012, BMC Genomics.

[108]  L. Chin,et al.  Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma , 2011, The Journal of experimental medicine.

[109]  G. Jenster,et al.  Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer , 2011, PloS one.

[110]  Pascal Barbry,et al.  Distinct epithelial gene expression phenotypes in childhood respiratory allergy , 2011, European Respiratory Journal.

[111]  B. Neel,et al.  TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. , 2011, Genes & development.

[112]  George Q. Daley,et al.  Lineage Regulators Direct BMP and Wnt Pathways to Cell-Specific Programs during Differentiation and Regeneration , 2011, Cell.

[113]  Davide Corà,et al.  Mulcom: a multiple comparison statistical test for microarray data in Bioconductor , 2011, BMC Bioinformatics.

[114]  S. Goldman,et al.  CD140a identifies a population of highly myelinogenic, migration-competent, and efficiently engrafting human oligodendrocyte progenitor cells , 2011, Nature Biotechnology.

[115]  Rainer Spang,et al.  Genomic data integration using guided clustering , 2011, Bioinform..

[116]  Christopher S. Chen,et al.  Decreased cell adhesion promotes angiogenesis in a Pyk2-dependent manner. , 2011, Experimental cell research.

[117]  Brian A. Kennedy,et al.  ChIP-seq Defined Genome-Wide Map of TGFβ/SMAD4 Targets: Implications with Clinical Outcome of Ovarian Cancer , 2011, PloS one.

[118]  M. Huynen,et al.  MicroRNA genes preferentially expressed in dendritic cells contain sites for conserved transcription factor binding motifs in their promoters , 2011, BMC Genomics.

[119]  Ru-Fang Yeh,et al.  TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer , 2011, Science Signaling.

[120]  Ernest Fraenkel,et al.  Genome-Wide Profiling of H3K56 Acetylation and Transcription Factor Binding Sites in Human Adipocytes , 2011, PloS one.

[121]  Xiuping Liu,et al.  The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. , 2011, Cancer research.

[122]  Peter J. Woolf,et al.  Time series gene expression profiling and temporal regulatory pathway analysis of BMP6 induced osteoblast differentiation and mineralization , 2011, BMC Systems Biology.

[123]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[124]  Rugang Zhang,et al.  Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. , 2011, Molecular cell.

[125]  Bing Ren,et al.  PU.1 and C/EBPα synergistically program distinct response to NF-κB activation through establishing monocyte specific enhancers , 2011, Proceedings of the National Academy of Sciences.

[126]  F. Novelli,et al.  Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. , 2011, Blood.

[127]  G. Mills,et al.  Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. , 2011, Cancer research.

[128]  A. Moran,et al.  Tribbles 3: A Novel Regulator of TLR2-Mediated Signaling in Response to Helicobacter pylori Lipopolysaccharide , 2011, The Journal of Immunology.

[129]  C. Maki,et al.  Pharmacologic activation of p53 by small-molecule MDM2 antagonists. , 2011, Current pharmaceutical design.

[130]  Lincoln Stein,et al.  Reactome: a database of reactions, pathways and biological processes , 2010, Nucleic Acids Res..

[131]  Salomon Amar,et al.  Bioinformatics Analysis of Macrophages Exposed to Porphyromonas gingivalis: Implications in Acute vs. Chronic Infections , 2010, PloS one.

[132]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[133]  Peter M. Schlag,et al.  Identification of Y-Box Binding Protein 1 As a Core Regulator of MEK/ERK Pathway-Dependent Gene Signatures in Colorectal Cancer Cells , 2010, PLoS genetics.

[134]  H. Kitano,et al.  Integrated Quantitative Analysis of the Phosphoproteome and Transcriptome in Tamoxifen-resistant Breast Cancer* , 2010, The Journal of Biological Chemistry.

[135]  Rafael A. Irizarry,et al.  A framework for oligonucleotide microarray preprocessing , 2010, Bioinform..

[136]  H. Mankin,et al.  Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer , 2010, Clinical Cancer Research.

[137]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[138]  B. Taylor,et al.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.

[139]  Lorenzo Rosasco,et al.  UvA-DARE ( Digital Academic Repository ) A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients , 2010 .

[140]  Mehmet Toner,et al.  Clinical Microfluidics for Neutrophil Genomics and Proteomics , 2010, Nature Medicine.

[141]  David J. Miller,et al.  Human Neuronal Cells Possess Functional Cytoplasmic and TLR-Mediated Innate Immune Pathways Influenced by Phosphatidylinositol-3 Kinase Signaling , 2010, The Journal of Immunology.

[142]  P. Rotwein,et al.  Soluble Repulsive Guidance Molecule c/Hemojuvelin Is a Broad Spectrum Bone Morphogenetic Protein (BMP) Antagonist and Inhibits both BMP2- and BMP6-mediated Signaling and Gene Expression* , 2010, The Journal of Biological Chemistry.

[143]  David Haussler,et al.  Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..

[144]  Bertram Klinger,et al.  Discovering causal signaling pathways through gene-expression patterns , 2010, Nucleic Acids Res..

[145]  P. Meltzer,et al.  Molecular and Cellular Pathobiology Cancer Research Hypoxia Modulates EWS-FLI 1 Transcriptional Signature and Enhances the Malignant Properties of Ewing ' s Sarcoma Cells In vitro , 2010 .

[146]  F. Döring,et al.  Identification of LPS‐inducible genes downregulated by ubiquinone in human THP‐1 monocytes , 2010, BioFactors.

[147]  Elias Campo Guerri,et al.  International network of cancer genome projects , 2010, Nature.

[148]  A. Chopra,et al.  Global Transcriptional Response of Macrophage-Like THP-1 Cells to Shiga Toxin Type 1 , 2010, Infection and Immunity.

[149]  W. Aird,et al.  Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3. , 2010, Blood.

[150]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[151]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[152]  A. Klein-Szanto,et al.  Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis. , 2010, Carcinogenesis.

[153]  Clifford A. Meyer,et al.  MYC regulation of a “poor-prognosis” metastatic cancer cell state , 2010, Proceedings of the National Academy of Sciences.

[154]  Neha Munjal,et al.  Gene Expression Profiling and Network Analysis Reveals Lipid and Steroid Metabolism to Be the Most Favored by TNFα in HepG2 Cells , 2010, PloS one.

[155]  J. Frasor,et al.  Correction: Positive Cross-Talk between Estrogen Receptor and NF-κB in Breast Cancer , 2010 .

[156]  G. Chan,et al.  Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility , 2009, Proceedings of the National Academy of Sciences.

[157]  H. Saya,et al.  Tumor Necrosis Factor-α Regulates Transforming Growth Factor-β-dependent Epithelial-Mesenchymal Transition by Promoting Hyaluronan-CD44-Moesin Interaction* , 2009, The Journal of Biological Chemistry.

[158]  Shuibang Wang,et al.  This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates... , 2009 .

[159]  J. Reis-Filho,et al.  Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma , 2009, Pigment cell & melanoma research.

[160]  J. Frasor,et al.  Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. , 2009, Cancer research.

[161]  N. Hacohen,et al.  A Physical and Regulatory Map of Host-Influenza Interactions Reveals Pathways in H1N1 Infection , 2009, Cell.

[162]  J. Banchereau,et al.  Ribosomal protein mRNAs are translationally-regulated during human dendritic cells activation by LPS , 2009, Immunome research.

[163]  Lorenzo Rosasco,et al.  The l1-l2 regularization framework unmasks the hypoxia signature hidden in the transcriptome of a set of heterogeneous neuroblastoma cell lines , 2009, BMC Genomics.

[164]  A. Kung,et al.  Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia , 2009, Genome Biology.

[165]  Joel Greshock,et al.  Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. , 2009, Cancer research.

[166]  P. Munson,et al.  Interleukin-27 inhibition of HIV-1 involves an intermediate induction of type I interferon. , 2009, Blood.

[167]  Reinhard Guthke,et al.  Adapted Boolean network models for extracellular matrix formation , 2009, BMC Systems Biology.

[168]  Wei Zhou,et al.  In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.

[169]  Matthew J Loza,et al.  Glucocorticoid- and protein kinase A-dependent transcriptome regulation in airway smooth muscle. , 2009, American journal of respiratory cell and molecular biology.

[170]  P. Khavari,et al.  Erk1/2 MAP kinases are required for epidermal G2/M progression , 2009, The Journal of cell biology.

[171]  Ahmed Essaghir,et al.  The Transcription of FOXO Genes Is Stimulated by FOXO3 and Repressed by Growth Factors* , 2009, Journal of Biological Chemistry.

[172]  Jeffrey T. Chang,et al.  A genomic strategy to elucidate modules of oncogenic pathway signaling networks. , 2009, Molecular cell.

[173]  Wei Zhao,et al.  Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1alpha and VEGF in laser-induced rat choroidal neovascularization. , 2009, Investigative ophthalmology & visual science.

[174]  M. Belvin,et al.  Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. , 2009, Cancer research.

[175]  C. Sander,et al.  V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.

[176]  K. Flaherty,et al.  HIF- α effects on c-Myc distinguish two subtypes of sporadic VHL -deficient clear cell renal carcinoma , 2009 .

[177]  Xiao-Fan Wang,et al.  Signaling cross-talk between TGF-β/BMP and other pathways , 2009, Cell Research.

[178]  Pooja Mittal,et al.  A novel signaling pathway impact analysis , 2009, Bioinform..

[179]  P. Colman,et al.  BCL-2 family antagonists for cancer therapy , 2008, Nature Reviews Drug Discovery.

[180]  M. West,et al.  The Genomic Analysis of Lactic Acidosis and Acidosis Response in Human Cancers , 2008, PLoS genetics.

[181]  A. Butte,et al.  Expression-based Pathway Signature Analysis (EPSA): Mining publicly available microarray data for insight into human disease , 2008, BMC Medical Genomics.

[182]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[183]  A. Rice,et al.  Cyclin T1-Dependent Genes in Activated CD4+ T and Macrophage Cell Lines Appear Enriched in HIV-1 Co-Factors , 2008, PloS one.

[184]  A. Corradin,et al.  The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. , 2008, Cancer research.

[185]  R. Homayouni,et al.  Transcriptome profile of the vascular endothelial cell response to Candida albicans. , 2008, The Journal of infectious diseases.

[186]  B. Pedersen,et al.  Calprotectin is released from human skeletal muscle tissue during exercise , 2008, The Journal of physiology.

[187]  Monica L Guzman,et al.  Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. , 2008, Blood.

[188]  Marcin Piechota,et al.  Identification of interleukin-1 and interleukin-6-responsive genes in human monocyte-derived macrophages using microarrays. , 2008, Biochimica et biophysica acta.

[189]  M. Blumenberg,et al.  Transcriptional profiling defines the roles of ERK and p38 kinases in epidermal keratinocytes , 2008, Journal of cellular physiology.

[190]  T. Pastinen,et al.  Systematic assessment of the human osteoblast transcriptome in resting and induced primary cells. , 2008, Physiological genomics.

[191]  R. Bernards,et al.  Enabling personalized cancer medicine through analysis of gene-expression patterns , 2008, Nature.

[192]  Shuang Huang,et al.  ATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis* , 2008, Journal of Biological Chemistry.

[193]  T. Hamilton,et al.  Platinum Resistance: The Role of DNA Repair Pathways , 2008, Clinical Cancer Research.

[194]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[195]  J. Tobias,et al.  Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. , 2008, Cancer research.

[196]  T. Golub,et al.  Gene expression-based screening for inhibitors of PDGFR signaling , 2008, Genome Biology.

[197]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[198]  G. Chan,et al.  Transcriptome Analysis of NF-κB- and Phosphatidylinositol 3-Kinase-Regulated Genes in Human Cytomegalovirus-Infected Monocytes , 2007, Journal of Virology.

[199]  M. Zvelebil,et al.  Exploring the specificity of the PI3K family inhibitor LY294002. , 2007, The Biochemical journal.

[200]  J. Davis.  Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[201]  Helen E. Parkinson,et al.  ArrayExpress—a public database of microarray experiments and gene expression profiles , 2006, Nucleic Acids Res..

[202]  M. Kuwano,et al.  Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs , 2006, Clinical Cancer Research.

[203]  Jerry M Maniate,et al.  Targeting the EGFR pathway for cancer therapy. , 2006, Current medicinal chemistry.

[204]  H. Ressom,et al.  Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA , 2006, Molecular and Cellular Biology.

[205]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[206]  Johannes Roth,et al.  TNF induces distinct gene expression programs in microvascular and macrovascular human endothelial cells , 2006, Journal of leukocyte biology.

[207]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[208]  D. Wujcik.  EGFR as a target: rationale for therapy. , 2006, Seminars in oncology nursing.

[209]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[210]  H. Ressom,et al.  Activation of p 53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK 3 CA , 2006 .

[211]  É. Álvarez,et al.  Inhibition of NF-κB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines , 2005 .

[212]  E. Benveniste,et al.  LPS induces CD40 gene expression through the activation of NF-κB and STAT-1α in macrophages and microglia , 2005 .

[213]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[214]  刘金明,et al.  IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A , 2005 .

[215]  D. Louis,et al.  Autocrine platelet-derived growth factor-dependent gene expression in glioblastoma cells is mediated largely by activation of the transcription factor sterol regulatory element binding protein and is associated with altered genotype and patient survival in human brain tumors. , 2005, Cancer research.

[216]  P. Krammer,et al.  Death receptor signaling , 2005, Journal of Cell Science.

[217]  Y. Adachi,et al.  Activation of Toll-Like Receptor-Mediated NF-κβ by Zymosan-Derived Water-Soluble Fraction: Possible Contribution of Endotoxin-Like Substances , 2005 .

[218]  Y. Adachi,et al.  Activation of toll-like receptor-mediated NF-kappa beta by zymosan-derived water-soluble fraction: possible contribution of endotoxin-like substances. , 2005, Immunopharmacology and immunotoxicology.

[219]  L. Trümper.  From bench to bedside , 2005, Medizinische Klinik.

[220]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[221]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[222]  M. Protopopova,et al.  Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.

[223]  U. Eriksson,et al.  The PDGF family: four gene products form five dimeric isoforms. , 2004, Cytokine & growth factor reviews.

[224]  P. Dijke,et al.  New insights into TGF-β–Smad signalling , 2004 .

[225]  B. Brüne,et al.  PI3K/Akt Is Required for Heat Shock Proteins to Protect Hypoxia-inducible Factor 1α from pVHL-independent Degradation* , 2004, Journal of Biological Chemistry.

[226]  Enrique Casado,et al.  PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.

[227]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[228]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[229]  B Marshall,et al.  Gene Ontology Consortium: The Gene Ontology (GO) database and informatics resource , 2004, Nucleic Acids Res..

[230]  B. Aggarwal.  Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[231]  D. Rifkin,et al.  Making sense of latent TGFbeta activation. , 2003, Journal of cell science.

[232]  D. Goeddel,et al.  TNF-R1 Signaling: A Beautiful Pathway , 2002, Science.

[233]  M. Cobb,et al.  Pharmacological inhibitors of MAPK pathways. , 2002, Trends in pharmacological sciences.

[234]  A. G. Ellis,et al.  High-performance liquid chromatographic analysis of the tyrphostin AG1478, a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in mouse plasma. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[235]  L. Claesson‐Welsh,et al.  FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. , 2001, Trends in pharmacological sciences.

[236]  G. Mcmahon,et al.  VEGF receptor signaling in tumor angiogenesis. , 2000, The oncologist.

[237]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[238]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[239]  P Bailey,et al.  Double Edged Sword , 2002 .

[240]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[241]  G. Semenza.  Hypoxia-inducible factor 1: master regulator of O2 homeostasis. , 1998, Current opinion in genetics & development.

[242]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[243]  Stephen J. Elledge,et al.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest , 1994, Cell.

[244]  M. Kastan,et al.  DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways , 1994, Molecular and cellular biology.

[245]  P. Chiaravelli.  Variations on a theme. , 1990, Journal of the American Dental Association.

[246]  D. Rifkin,et al.  Recent developments in the cell biology of basic fibroblast growth factor , 1989, The Journal of cell biology.